Evaluating Efficacy and Tolerability of Anticancer Drug Therapies for the Treatment of Gynecologic and Breast Cancers

Launched by IRCCS AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA · Jan 28, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness and safety of different cancer drug therapies for treating breast and gynecologic cancers, which include early-stage and metastatic breast cancer, ovarian cancer, cervical cancer, and endometrial cancer. The goal is to understand how well these drugs work in helping patients live longer and have fewer side effects compared to previous studies. Researchers will look at various outcomes, such as how many patients respond to the treatment and how long they stay free from disease.

To qualify for this trial, participants need to have a confirmed diagnosis of breast or gynecologic cancer, whether at an early stage or more advanced. Patients should have received treatment for their cancer since January 2010 and must be reachable to give their consent for participation. There are no specific exclusions, meaning anyone who meets these criteria can join. Participants can expect to provide information about their treatment experiences and may contribute to important findings that could help improve cancer care for others in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of histologically confirmed breast cancer or gynecological cancer, either early stage or metastatic;
• • Patients who have received treatment for breast cancer or gynecologic cancer since January 2010;
• • Any patient currently living and actually contactable must sign an informed consent to the study and processing of personal data.
• Exclusion Criteria:
• • no exclusion criteria